Influenza News and Research

Latest Influenza News and Research

FDA recommends H1N1 for inclusion in next year's flu vaccine

The U.S. Food and Drug Administration (FDA) on Monday recommended that the H1N1 (swine flu) strain be added to next year's seasonal flu vaccine, "putting an end to separate shots deployed against the pandemic," Bloomberg reports. The FDA committee voted unanimously to make the H1N1 strain one of the three strains included in the shot, according to the news service. "The panel's recommendations are routinely adopted and used to guide vaccine manufacturers," Bloomberg writes (Randall, 2/22).

24 Feb 2010

NanoViricides files quarterly report with Securities and Exchange Commission

NanoViricides, Inc. has filed its quarterly report with the Securities and Exchange Commission yesterday in a timely fashion.

24 Feb 2010

FDA grants EUA for Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay in CLIA high complexity laboratories

Longhorn Vaccines & Diagnostics today announced it has been granted Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ in CLIA high complexity laboratories. . The Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay™ is a ready-use assay that requires no mixing prior to use and has been authorized for use on the ABI 7500.

24 Feb 2010

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Diagnostic Hybrids, a Quidel Company has received emergency use authorization from the U.S. Food and Drug Administration for its D3® UltraTM 2009 H1N1 Influenza A Virus ID Kit, a monoclonal antibody fluorescent staining kit for the specific identification of 2009 H1N1 influenza A in direct patient specimens or incubated tissue cultures.

23 Feb 2010

Henry Schein announces net sales increase of 13.0% for fourth-quarter 2009

Henry Schein, Inc., the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended December 26, 2009.

23 Feb 2010

TCAD therapy active and synergistic against drug resistant influenza virus strains

Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.

23 Feb 2010

Research reveals human Chlamydia pneumoniae has originated from animal source

Animals have been found to have infected humans sometime in the past with the common respiratory disease Chlamydia pneumoniae, according to Queensland University of Technology infectious disease expert Professor Peter Timms.

23 Feb 2010

PositiveID, RECEPTORS announce successful completion of rapid virus detection system Phase I development

PositiveID Corporation, in conjunction with its development partner RECEPTORS LLC, announced today that it has successfully completed Phase I development of its rapid virus detection system, a non-invasive, point-of-care test to test patient samples and identify various forms of influenza within minutes. Phase II of the development, which the Company expects to complete by the end of 2010, is planned to launch in February 2010.

23 Feb 2010

ASU epidemiologist to take close look at factors impacting influenza dynamics within Mexico

Influenza surveillance mechanisms in Mexico were adequate during the fast-spreading H1N1 outbreak in 2009, yet Mexico did not have the infrastructure to quickly identify the emergence of this novel strain, according to an Arizona State University (ASU) epidemiologist.

21 Feb 2010

Quidel acquires Diagnostic Hybrids for $130 million

Quidel Corporation, a leading provider of rapid diagnostic tests, has completed its previously announced acquisition of Diagnostic Hybrids, Inc. for approximately $130 million in cash.

20 Feb 2010

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

BioCrossroads' Indiana Seed Fund has invested in Bioscience Vaccines, Inc. to accelerate the development of biologic materials, which may boost the effectiveness of a wide range of life-saving vaccines.

19 Feb 2010

CMAJ study summarizes risk factors for severe outcome among patients admitted to hospital with H1N1

A new study in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/cgi/doi/10.1503/cmaj.091823 of all patients in Canada admitted to hospital for H1N1 in the first five months of the outbreak summarizes the risk factors for a severe outcome (www.cmaj.ca). The H1N1 pandemic presents important learnings for clinicians and researchers and data on severe outcomes can help inform future treatment and prevention guidelines.

19 Feb 2010

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Novavax, Inc. today presented to the world's leading pandemic influenza vaccine experts a summary of the recent preliminary safety and immunogenicity data from its Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study in Mexico.

19 Feb 2010

Amerigroup's fourth-quarter revenues rise 18.5%

Amerigroup Corporation today announced that net income for the fourth quarter of 2009 was $40.2 million, or $0.79 per diluted share, versus $35.9 million, or $0.67 per diluted share, for the fourth quarter of 2008. For the year ended December 31, 2009, the Company's net income was $149.3 million, or $2.85 per diluted share.

19 Feb 2010

Sacred Heart Medical Center fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards

On January 29, 2010, Sacred Heart Medical Center was cited and fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards. The Department of Labor and Industries Division of Occupational Safety and Health issued the citation and fine for violation of Center for Disease Control and Occupational Safety and Health Administration guidelines on H1N1 and also for violation of the DOSH Directive on Enforcement Procedures for High or Very High Occupational Exposure Risk to the 2009 H1N1 Influenza.

19 Feb 2010

Gentel Biosciences launches integrated Proteomics Multi-System

Gentel Biosciences, a leader in proteomics discovery tools, today launched the Gentel Proteomics Multi-System™ providing “scan-to-analysis” functionality for multiplex immunoassays, lysate and antigen arrays as well as Western Blot, ELISA and tissue imaging, delivering multi-application value to researchers worldwide.

19 Feb 2010

WHO recommends H1N1 be added to next year's seasonal flu virus

The WHO is recommending the H1N1 (swine flu) virus be added to the regular flu vaccine for the Northern Hemisphere's 2010-2011 regular flu season, the Associated Press reports (2/18).

19 Feb 2010

AltraVax acquires vaccine development technology package from Maxygen

AltraVax, Inc., a new, privately-held biopharmaceutical company, has acquired a vaccine development technology package from Maxygen, Inc. that gives AltraVax an exclusive license to develop vaccines for infectious diseases and is targeting influenza, a treatment for hepatitis B and HIV.

18 Feb 2010

Travellers are likely to become increasingly exposed to canecutter's disease: Study

A team led by PhD researcher Dr Colleen Lau from the School of Population Health http://www.sph.uq.edu.au/ , has discovered the disease, known medically as leptospirosis, was traditionally a concern for males working in the agricultural and livestock industries, as it is contracted from contact with the urine of host animals.

18 Feb 2010

Viral infection can suppress immune response to secondary bacterial infection

A new study reveals how infection with the influenza virus impacts the way that the immune system responds to subsequent infections. The research, published by Cell Press in the February 18th issue of the journal Cell Host and Microbe, provides a new understanding of the physiological and pathological consequences of the flu.

18 Feb 2010

Influenza News and Research

Latest Influenza News and Research

FDA recommends H1N1 for inclusion in next year's flu vaccine

NanoViricides files quarterly report with Securities and Exchange Commission

FDA grants EUA for Longhorn Influenza A/H1N1-09 Prime RRT-PCR Assay in CLIA high complexity laboratories

FDA grants Diagnostic Hybrids emergency use authorization for 2009 H1N1 Influenza A Virus ID Kit

Henry Schein announces net sales increase of 13.0% for fourth-quarter 2009

TCAD therapy active and synergistic against drug resistant influenza virus strains

Research reveals human Chlamydia pneumoniae has originated from animal source

PositiveID, RECEPTORS announce successful completion of rapid virus detection system Phase I development

ASU epidemiologist to take close look at factors impacting influenza dynamics within Mexico

Quidel acquires Diagnostic Hybrids for $130 million

BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines

CMAJ study summarizes risk factors for severe outcome among patients admitted to hospital with H1N1

Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting

Amerigroup's fourth-quarter revenues rise 18.5%

Sacred Heart Medical Center fined $8,000 for failing to adhere to state and national H1N1 influenza safety standards

Gentel Biosciences launches integrated Proteomics Multi-System

WHO recommends H1N1 be added to next year's seasonal flu virus

AltraVax acquires vaccine development technology package from Maxygen

Travellers are likely to become increasingly exposed to canecutter's disease: Study

Viral infection can suppress immune response to secondary bacterial infection

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Influenza News and Research

Latest Influenza News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in